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Commentaries use of the phrase "perindopril-based" treatment is misleading, since perindopril without indapamide showed no benefit for stroke prevention.
[ [2] [3] [4] In PROGRESS, patients randomized to receive treatment could receive either of two different antihypertensive regimens: (a) perindopril (4 mg/day) or, (b) perindopril (4 mg/day) plus indapamide (2.5 mg/day). Compared to placebo, perindopril alone showed no benefit (Chi-square = 0.235, P=0.63). Perindopril plus indapamide, however, showed a highly significant benefit (Chi-square = 30.468, P<0.0001).
However, the authors do not report separately the results of their subgroups of perindopril with or without indapamide. If the results are similar to those of the PROGRESS trial, as the authors claim, then it is possible that only the group treated with perindopril plus indapamide benefited in terms of stroke prevention.
The curious practice of having a "flexible" regimen where a known stroke protective drug (indapamide)
[6] may or may not be added to one which is not yet proven (perindopril) -and then amalgamating the results so that indapamide.
it is unclear which drug is responsible for the benefit -is The two treatment regimens in PROGRESS were misleading and should not be repeated. Future studies amalgamated and presented as the effects of "perindopril-should either remove indapamide from the protocol (if based" antihypertensive therapy.
[1] The amalgamated perindopril is truly the drug of interest) or include results showed a significant benefit of treatment compared indapamide monotherapy as a treatment option. Only to placebo (Chi-square = 19.812, P<0.0001) despite the then will we be able to truly differentiate the active lack of effect of perindopril monotherapy due to the highly component(s) of "PROGRESS-based" treatment and make significant benefit of treatment with perindopril plus the best possible medical and economic decisions for the widespread prevention of recurrent stroke. In this issue of Neurology India, the results of an observational, multicenter study performed in the setting R. A. Wennberg, C. Zimmermann of primary care throughout India are presented.
[5] The
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described in the PROGRESS trial would be reflected in indapamide may be effective to prevent recurrent stroke Lancet 2001; 358:1033-41. in the Indian primary care setting.
[5] There was no control 2. Wennberg R, Zimmermann C. The PROGRESS trial three years group however, and so the study does not provide direct
